Formulary guidance and transparency from P&T to point of care


Reality Check on Carcinoid Syndrome

Market access for carcinoid syndrome treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, almost 56% of the lives under commercial formularies are covered with utilization management restrictions
  • Class Trends: In June 2019, the FDA approved a new prefilled syringe for Ipsen Biopharmaceuticals, Inc.’s Somatuline Depot (lanreotide), which includes updated features to help health care providers administer the injection  
  • Key Findings: Competition in this indication often surrounds coverage label as compared to label, preferred specialty tier status and whether policies require increased dosages of Sandostatin  

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.